Business Description
Altimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US02155H2004
Total Employee Number:
57Compare
Compare
Traded in other countries / regions
ALT.USA3G0.Germany0A4C.UKALT1.Mexico Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2005-10-06Description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.25 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.41 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.58 | |||||
Beneish M-Score | -3.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.1 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 16.9 | |||||
3-Year Book Growth Rate | -18.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.04 | |||||
9-Day RSI | 71.65 | |||||
14-Day RSI | 63.61 | |||||
3-1 Month Momentum % | -3.53 | |||||
6-1 Month Momentum % | -16.62 | |||||
12-1 Month Momentum % | -28.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 29.56 | |||||
Quick Ratio | 29.56 | |||||
Cash Ratio | 29.28 | |||||
Days Sales Outstanding | 9240.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.1 | |||||
Shareholder Yield % | -39.66 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -269216.67 | |||||
Net Margin % | -253002.78 | |||||
EBITDA Margin % | -245200 | |||||
FCF Margin % | -199050 | |||||
OCF Margin % | -198991.67 | |||||
ROE % | -45.63 | |||||
ROA % | -38.54 | |||||
ROIC % | -4993.71 | |||||
3-Year ROIIC % | 49.49 | |||||
ROC (Joel Greenblatt) % | -27532.09 | |||||
ROCE % | -39.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.44 | |||||
Price-to-Tangible-Book | 1.44 | |||||
EV-to-EBIT | -3.56 | |||||
EV-to-EBITDA | -3.57 | |||||
EV-to-Forward-EBITDA | -2.67 | |||||
EV-to-Revenue | 8748.78 | |||||
EV-to-Forward-Revenue | 22503.7 | |||||
EV-to-FCF | -4.4 | |||||
| Price-to-Net-Current-Asset-Value | 1.45 | |||||
| Price-to-Net-Cash | 1.46 | |||||
Earnings Yield (Greenblatt) % | -28.09 | |||||
FCF Yield % | -11.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altimmune Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.036 | ||
| EPS (TTM) ($) | -0.93 | ||
| Beta | 3.2482 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 1.08 | ||
| Volatility % | 86.7 | ||
| 14-Day RSI | 63.61 | ||
| 14-Day ATR ($) | 0.168267 | ||
| 20-Day SMA ($) | 2.795 | ||
| 12-1 Month Momentum % | -28.84 | ||
| 52-Week Range ($) | 2.56 - 6.4399 | ||
| Shares Outstanding (Mil) | 194.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altimmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altimmune Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 127 days | ||
| General meeting for 2026 | 2026-09-25 08:30 | In 86 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 41 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:00 | 2.66 (-3.83%) | ||
| Guidance call for 2026 | 2026-06-04 12:50 | 2.87 (-2.05%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:30 | 3.08 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 3.08 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 10:30 | 3.80 (-2.31%) |
Show
Entries
Altimmune Inc Frequently Asked Questions
What is Altimmune Inc(ALT)'s stock price today?
The current price of ALT is $3.14. The 52 week high of ALT is $6.44 and 52 week low is $2.56.
When is next earnings date of Altimmune Inc(ALT)?
The next earnings date of Altimmune Inc(ALT) is 2026-08-12 Est..
Does Altimmune Inc(ALT) pay dividends? If so, how much?
Altimmune Inc(ALT) does not pay dividend.
Guru Commentaries on NAS:ALT
No articles.
Press Release
Articles on Altimmune Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
Altimmune shifts headquarters to New Jersey, targeting biopharma talent and cost savings
Seeking Alpha • 5:56am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers